SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " biotech " 225 found 🔀 AI-powered Shuffle
National High Magnetic Field Laboratory will develop cutting-edge nuclear magnetic resonance facility with $18M in funding
The project supports National Science Foundation priorities in biotechnology, energy, advanced manufacturing and health The National High Magnetic Field
Call for Abstracts — 2027 Petrie-Flom Center Annual Conference: Generative AI in Healthcare: Law & Regulation - Petrie-Flom Center
The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School is pleased to announce our 2027 Annual Conference, Generative AI in Healthcare: Law and Regulation. Generative AI –- artificial intelligence designed to produce output, such as text or images, that normally require human intelligence — has become a…
Why we’re still so obsessed with Elizabeth Holmes
You Can See Everything, a documentary about the disgraced biotech company founder Elizabeth Holmes, has enjoyed a record-breaking opening in the US. It is a testament to how fascinated we remain by the convicted fraudster, but what is behind the enduring appeal? US technology editor Blake Montgomery tells Madeleine Finlay why Holmes continues to fascinate us, and reflects on whether the Theranos scandal has had a permanent impact on Silicon Valley
China biotech RiboX reveals first data of circular RNA therapies in people
RiboX Therapeutics published first circular RNA clinical data in NEJM, showing RXRG001 improved saliva in xerostomia patients, ahead of Orna, Orbital, and Sail Biomedicines.
OpenAI acquired biotech startup Orchestra Bio to expand its life sciences AI tools
OpenAI will fold Orchestra's team and technology into Rosalind, its AI models and tools for life sciences researchers
New Richland Lab Could Transform How Scientists Study Microbes and Boost Regional Jobs
The BriefGroundbreaking held Tuesday: PNNL officially began construction on the M2PC lab, a 30,800-square-foot facility funded by the U.S. Department of Energy's Office of Science that will study soil microbes to improve crop productivity and develop new biotechnology applications. The facility will be open to researchers from around the nation and the world.Research timelines could shrink dramatically: The facility's automation and AI capabilities could reduce experiments that currently take six months to just 72 hours, allowing scientists to explore more possibilities faster than ever before.New jobs coming to the Tri-Cities: The project is expected to create positions for automation engineers, AI experts, roboticists, technicians, and skilled craftspeople, with the facility opening in 2029.RICHLAND, Wash. — Pacific Northwest National Laboratory broke ground Tuesday on a first-of-its-kind facility that could accelerate scientific discoveries about the microscopic organisms living in soil—organisms that may hold the key to growing more food and developing new energy technologies.The Microbial Molecular Phenotyping Capability, or M2PC, represents a significant investment in automation and artificial intelligence to speed up research that traditionally takes years to complete. The 30,800-square-foot facility will house more than 100 connected automated instruments designed to study microbes at a pace and scale never before possible.Reshaping Agriculture's FutureThe M2PC facility will not put a new tool directly into a farmer's hands tomorrow morning, but it is actively reshaping the commercial pipeline to solve agriculture's biggest headache with biologicals: inconsistent field performance. For years, PNNL researchers have explored how microbes work and how they might help produce useful materials, advance energy technologies, and address challenges involving critical materials and minerals. But those experiments have been limited by what researchers could accomplish by hand."They can be used to provide nutrients to a plant so that the plant would grow more. So, like increasing your crop productivity, for example," said Douglas Mans, PNNL's Associate Laboratory Director for Integrated Discovery Sciences.PNNL's own research shows soil microbes can help plants access nutrients and withstand drought—benefits that could prove crucial as farmers face growing environmental pressures. The M2PC facility will allow scientists to identify and optimize useful microbes faster than ever before, accelerating the development of biological solutions that actually work consistently in the field.What Makes M2PC UniqueThe Microbial Molecular Phenotyping Capability differs from traditional research labs because it operates as a first-of-its-kind, AI-enabled autonomous laboratory designed to shrink experimental timelines from years down to months or weeks. The M2PC lab will connect more than 100 automated instruments to grow microbes, prepare samples, measure their behavior, and link observations to the molecular processes behind them. Artificial intelligence will help analyze results and guide the next experiments, allowing scientists to explore more questions faster.Deb Gracio, PNNL Director, emphasized the transformative potential during Tuesday's groundbreaking ceremony: "Research that has taken years will become possible in months and hopefully in weeks."That acceleration is already being demonstrated. PNNL's smaller automated lab, called the Anaerobic Microbial Phenotyping Platform or AMP2, completed three experimental cycles in just 72 hours—a process that normally would have taken about six months."That normally would have taken us about six months … and we were able to do that in 72 hours," Mans said.The AMP2 laboratory is not being closed or replaced. Instead, the current 1,800-square-foot laboratory serves as an active prototype and precursor for the much larger M2PC facility. AMP2 will continue operating as a separate lab designed to run anaerobic experiments—those conducted in the absence of oxygen—while M2PC will focus on aerobic research.Broader Applications Beyond AgricultureWhile improving crop productivity is one important application, the M2PC facility is designed to support research into multiple areas critical to national priorities. The lab will advance research into biofuels, manufacturing materials, and energy technologies. It will also help researchers understand how microbes respond to environmental changes and how to design biological systems for biotechnology applications.As a flagship component of the Department of Energy's Genesis Mission, M2PC represents a significant investment in using artificial intelligence and automation to accelerate U.S. scientific discovery. Dorothy Koch, Associate Director of the DOE Office of Science Biological and Environmental Research program, highlighted the facility's importance during the groundbreaking."M2PC will accelerate biological discovery and design," Koch said, noting that the facility is expected to conduct a minimum of 500 strain experiments per week, 100 microbiome experiments per week, and take a million measurements per month.Economic Opportunity for the RegionBeyond the scientific breakthroughs, the M2PC project represents significant economic opportunity for the Tri-Cities region. The facility will require hiring automation engineers, AI experts, technicians skilled in operating robotics, and specialized craftspeople to build and maintain the sophisticated equipment."We're anticipating that type of hiring," Mans said when asked about job creation.PNNL has already begun recruiting talent nationally and internationally for positions related to the smaller AMP2 lab, bringing automation engineers from cities like Boston and San Francisco to work in the region. The M2PC facility is expected to accelerate that trend."This capability won't really exist anywhere else in the world," Mans said, suggesting the facility could become a draw for scientific talent seeking to work on cutting-edge biotechnology research.Timeline and Next StepsThe M2PC facility is expected to open in 2029. Between now and then, construction crews will level and prepare the ground, while the building takes shape. Simultaneously, Ginkgo Bio Works, the automation contractor, will build the facility's automation components off-site so they can be installed as the building is completed.In the interim, PNNL researchers and the broader scientific community will begin planning the first experiments to be conducted in the facility, ensuring research is lined up and ready to begin as soon as the doors open.The groundbreaking ceremony included representatives from the Department of Energy, PNNL leadership, and elected officials at the federal, state, and local levels, underscoring the project's significance to the region and the nation's biotechnology future. News The U.S. Department of Energy Secretary tours Pacific Northwest National Laboratory Dan Hanson, Apple Valley News Now News Beyond DNA: Scientists Explore New Frontiers in Biology Research Dan Hanson, Apple Valley News Now News TRIDEC optimistic that Hanford, PNNL will see funding in national budget Robert Desaulniers News Big picture science: monitoring the Yakima River Basin News PNNL research could shape the future of fighting fentanyl COPYRIGHT 2026 BY APPLE VALLEY NEWS NOW. ALL RIGHTS RESERVED. THIS MATERIAL MAY NOT BE PUBLISHED, BROADCAST, REWRITTEN OR REDISTRIBUTED.
OpenAI acquires startup Orchestra Bio to beef up its biotech business
OpenAI says it's adding Orchestra's team and technology to work on Rosalind, its AI model for life sciences research, and to its related Rosalind Workbench tool, a harness that aims to help researchers plan experiments and analyze results.
INOVIO Announces Favorable Judgment in Litigation with VGXI, Inc. and GeneOne Life Science
/PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and...
Biotech firm Colossal set to return extinct bird’s egg to New Zealand
The biotech firm trying to bring extinct species back to life, Colossal Biosciences Inc., will return an egg from the flightless moa to its native New Zealand.
Pfizer makes ‘business decision’ to end phase 2 trial of autoimmune drug as program’s future uncertain
Pfizer has called time on a phase 2 trial of its CXCR5 antibody in an autoimmune blood disorder, with the company tight-lipped on whether this marks the end of the road for the asset. The Big Pharma had been evaluating the therapy, dubbed PF-06835375, in a phase 2 study of 61 patients with primary immune thrombocytopenia (ITP) that kicked off in 2022, according to the federal trials register. However, Pfizer confirmed to Fierce on Monday that this study had been terminated “due to a business decision.” “The decision to terminate the trial was not based on any safety concerns,” a spokesperson pointed out. At time of publication, PF-06835375 remained listed on Pfizer’s website for both ITP and lupus. A phase 1 study in lupus wrapped up in 2022, according to the trials database. ITP is an autoimmune disorder characterized by a low platelet count. Novartis was at one point evaluating its B-cell-depleting antibody ianalumab—recently approved as Fabhalta to treat immunoglobulin A nephropathy—as a potential treatment ITP. But the therapy struggled to demonstrate a benefit in the clinic for this indication. When contacted by Fierce, Pfizer wouldn’t confirm whether all work on PF-06835375 has been halted, and whether the company has any other plans to explore C-X-C chemokine receptor type 5 (CXCR5) as a mechanism. CXCR5 is found in blood cancers such as diffuse large B-cell lymphoma and mantle cell lymphoma chemokine receptor. However, there is little expression in normal tissue, which has led some drug developers to explore its potential. Vincerx Pharma had at one point been planning to take an anti-CXCR5 ADC into the clinic to treat B-cell malignancies, but that ambition was scrapped due to cash constraints. Where Big Pharma is placing its bets is one of the hot topics being discussed at Fierce Biotech's high-impact event in London next month. Find out more information and register by clicking on the banner below: [ ](https://qtxasset.com/quartz/qcloud5/media/image/where_big_pharma_is_placing_its_bets.png?VersionId=B8JrRbJ.pFUSK1pJgjeWHLGm_18RdLAy)
TriGemX Bio and TCGX Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Company to Develop Elismetrep, A Potential First-in-Class Treatment for Migraine
TriGemX Bio, a biotechnology company focused on developing elismetrep, a potential first-in-class treatment for migraine, and TCGX Acquisition Corp. (Nasdaq:...
SMC's Distinguished Scientists Series Returns: Biotech & USC Talks
Free science lectures at Santa Monica College on Oct. 20 and Nov. 19 featuring biotech executives and USC researchers discussing precision medicine and gene therapy.
Vietnamese scientist wins ASEAN-US Science Prize for Women
Associate Professor Ha Thị Thanh Huong graduated with top grade in biotechnology from the University of Science under Vietnam National University, HCM City.
Daldrop Opens for Business in Southern Oswego County
$10 Million Facility in the L. Michael Treadwell Oswego County Industrial Park marks the largest expansion outside of Germany in the company’s 73-year history By Stefan Yablonski [caption id=attachment_11076 align=alignright width=450] Daldrop SBB CEO Jens Daldrop addresses attendees at the 2025 groundbreaking for the project. Daldrop also chairs the advisory board of Germany-based Daldrop Group.[/caption] A new era of cleanroom technology is underway in Central New York. The Daldrop Group’s advanced manufacturing facility and U.S. headquarters is physically built within the L. Michael Treadwell Oswego County Industrial Park. This industrial park is located in the town of Schroeppel. It marks the largest expansion outside of Germany in the company’s 73-year history. Daldrop SBB is based in Neckartailfingen, Germany. It is a global supplier of cleanroom technology, primarily to the pharmaceutical industry. It designs and builds advanced cleanroom environments for the pharmaceutical, biotechnology and medical technology industries. It nvested $10 million in the new project. “We broke ground in 2025; we were under construction all winter. We just opened this spring, early spring,” said Benjamin Morrow, operations manager and control. The company consolidated sites in Salina and DeWitt into the industrial park in Schroeppel, Morrow added. “The next move here is to maximize every square inch of this facility and then we are already looking at the expansion. So, it is more capital investment on equipment — definitely higher-end automation in additional equipment so we can produce more components and then to support the ever-growing base in North America,” Morrow continued. “We are the headquarters for service, maintenance and spare parts. So as Daldrop has more and more installations, they need more and more service, maintenance and spare parts. So that will come out of this facility as well — it already is.” “As a global leader in GMP (global manufacturing support) pharmaceutical cleanrooms for decades, I am very proud to bring manufacturing jobs to Upstate New York,” said Mike Sullivan, president of Daldrop US operations. Key to choosing Southern Oswego County [caption id=attachment_11077 align=alignright width=450] Daldrop SBB at the L. Michael Treadwell Oswego County Industrial Park when the company announced the start of construction.[/caption] Sullivan said that the selection of the Schroeppel industrial park was mainly due to the help of Operation Oswego County and two people in the organization. “Prior to being purchased by Daldrop International from the Stuttgart region of Germany, Vince Bongio was a founding partner in SBB Inc. as well as our head of engineering. We based out of Syracuse due to Vince’s skills in HVAC and the manufacturing capabilities found in Syracuse,” said Sullivan. Bongio moved to Syracuse from California in the 1970s to work in Carrier’s Industrial Division of Large-Scale Petrochemical Refrigeration. Next, he advanced to General Electric’s TV Tube Plant where he got into cleanrooms ,leading to his role of head of engineering for Clestra Cleanrooms where he met Sullivan, their New England distributor. “Vince Bongio is a phenomenal engineer. Formerly of Carrier, he grew up in California and went to Cal Poly,” Sullivan explained. “Carrier hired him right out of college and he moved to Syracuse. He is the reason we are in Syracuse today. He is retiring this year. We are very proud and his legacy is having brought Daldrop to Syracuse.” In 2000, Sullivan, Bazinet, Bongio Inc (SBB) was formed with engineering and manufacturing, based in Syracuse, and sales and construction based in Massachusetts as it is today. “SBB Inc. started in Syracuse. I had a design–build contracting firm out of Massachusetts that was primarily doing all the new technologies coming out of MIT,” Sullivan said. “I started a manufacturing side. A big thing for cleanrooms is the HVAC. Most cleanroom suppliers are architecturally focused people. The strength in Syracuse is HVAC. So, SBB developed with me running sales and construction out of Massachusetts and manufacturing out of Syracuse.” “Daldrop wanted to have a relationship in the States and of those who approached us, they were the only ones who really understood HVAC. So, we were the right fit for them. We did a joint venture focused out of Massachusetts from 2012 to 2018 leveraging their technologies,” Sullivan explained. “The commitment was if we brought their product to the States, we would do that if they built it here. “The pieces that had to be in place to make the investment, they wanted to acquire us, we were great with that. If you looked at business recommendations the general guidance was to build in a low labor area — something like North Carolina — but Syracuse had a strong background in HVAC and we chose Syracuse and Oswego County to be our headquarters in the States. So, it is built off of history, technology and the existing supply chain — bringing jobs back to the area.” During the initial discussions with Daldrop about coming to the U.S., SBB agreed to sell under the conditions Daldrop would manufacture in the U.S. There are many areas that offer incentives and economic packages, but the strength of HVAC expertise and skilled manufacturing was a big part of the discussions for site selection. Coming home [caption id=attachment_11078 align=alignright width=451] Construction moves forward in March at the L. Michael Treadwell Oswego County Industrial Park.[/caption] The second key person to building in Oswego County is Ben Morrow, Sullivan added. “Ben has been working with Daldrop SBB for more than 12 years and has advanced to COO of manufacturing and engineering. Ben grew up in Phoenix, so building a factory for the Germany company in Phoenix is a strong success for both his community and the appreciation of Ben’s skills as a team leader,” Sullivan said. “I went to high school in Phoenix. So, this is like full circle for me. It’s a small world,” Morrow said. “I hadn’t been back to Phoenix since graduation. This is one of the properties that John Trimble of C&S, he is the former president of C&S, he just retired, suggested. He and I were very good personal friends. John was from Mexico and I was from Phoenix. We knew each other from high school. And the architect of this building, Ed Smart of smartDESIGN Architecture in Batavia — I went to high school with him. So, this was a project that’s full circle a coming home kind of thing. The three of us knew each other — kind of like it was meant to be. Very serendipitous.” Schroeppel was one option for Daldrop to consider; the original intent was just to get a warehouse to store some product, he added. The facility is Daldrop’s largest outside of their native country. Total payroll at the facility will be approximately $2.4 million once fully staffed. “Here is 32,000 square feet and we plan to expand and put in an additional 10,000 square feet,” Morrow said. “We have 17.5 acres. We can put at least three more facilities here, just on this property. The master plan submitted for the current building is the first of possible three buildings on the campus.” “If we can find the right people and advance the production according to the plan, we should be able to grow for the next decade. One of the first jobs we filled was our new HR manager, with a primary focus posting and filling new positions,” Sullivan said. Stop the exodus, start hiring [caption id=attachment_11080 align=alignright width=452] Principals at the local Daldrop SBB headquarters, from left: Ben Morrow, Mike Sullivan and Jens Daldrop.[/caption] “I have been coming to Syracuse for 30 years. One of the things I had a hard time watching was the exodus of factories. One of the toughest things is to watch it with my partners’ kids who had to move away for jobs. It is important for us to give opportunity where people’s kids don’t have to leave the area to get work,” Sullivan said. “My responsibility is to find people who have skill sets that want to work and then I have to build opportunity for that work to happen. “After years of watching companies and Vince’s three sons all move out of the areas to get jobs, it is important to us to provide opportunities for the Syracuse region and help grow our company. We have been hiring for our new factory and will continue for the next few years.” “We are hiring and will continue to hire. Currently we have about 19 on staff right now,” Morrow said. “We expect to grow that by about 10 to 15 in the next 12 to 18 months or so. We are at 19 currently — one in the wings. It’s been great being able to hire locally. All these folks that we’ve been hiring, they all live within a few miles from here.” “We hired someone this past week (end of August). She grew up in the area, raised a family and is working down in Florida. She just took a job with us so she can move back and be with her family. We will be moving her back and she should be starting in October. We are very happy to see this happen,” Sullivan said. “I feel strongly about having a spot for the kids to not have to move out of the area. It is better to have people moving into the area.” Currently, Daldrop SBB has openings for finance manager, COO of construction and delivery, as well as mechanical, electrical designers and Revit modelers, construction managers, commissioning agents and many other skills that are needed. Along with Daldrop’s reputation in life science cleanrooms, there is a strong history in semiconductor, electronics, glass, photonics, aerospace and other markets. This may be helpful with any new technologies building in the market such as the Micron expansion and the support network, Sullivan said. “We acquired this property and closed on it two months before any announcement from Micron. It is serendipitous that they’re right down the street from us,” Morrow added. “Everybody started thinking ‘you guys are supporting Micron.’ We were here first. That is not a goal of ours. We may or may not … they are talking to us; it is an opportunity.” The long run [caption id=attachment_11079 align=alignright width=450] Benjamin Morrow, operations manager and control at Daldlrop, speaks during a recent ribbon-cutting event in Schroeppel.[/caption] “Long term, we will expand the Phoenix facility,” Sullivan said. “We built our facility with a campus approach. Sustainability is big. We designed our rooms to be more sustainable. Our building has no gas lines for heat. We put geothermal wells in the ground. We put heat pumps in for heating and cooling out of those wells and we put a large layer of solar panels up on the roof. We worked with National Grid for metering. Our building is a high efficiency model. We upgraded all the instillation and the glass filtering. So, it is a very green building. We will have a very minimal carbon footprint. It also adheres to LEED (Leadership in Energy and Environmental Design) construction standards.” “We are a bunch of HVAC engineers. We did a large scale geothermal and spent the money up front because we knew it made sense in the business sense in the environmental sense and sustainability,” Morrow said. “We have insulated metal panels on walls and roof; we are an envelope from the exterior.” Daldrop, as a global player, has a strong culture of sustainability that is found in all its products including the new facility. The building has been designed with (sixteen) 400-foot deep geothermal wells, high efficiency construction methods, approximately 70 kilowatt solar photovoltaic panels, electric vehicle chargers and 26% recycled content. “Daldrop thinks of long-term investing,” Sullivan said. “On the roof, photovoltaic panels supplement our power. Over half the energy that I use is coming from the sun. We have chargers up front for employee electric vehicles. This place is built to last. This slab that we are walking on, normal buildings are four inches, some go to six inches, we are nine inches all the way through — except where the heavy equipment is — that is 10 to 12 inches thick, solid concrete. It allows us to reconfigure for whatever type of equipment we want to bring in,” Morrow said. “We are authorized by Underwriters Laboratory to self-certify so we don’t need to have an inspector come out and recertify. We get audited often, but we certify our own electronics. The control system in this building is rather high-end. Our thermostat in every room is zoned, independent. We analyze the data; incorporate it with our solar panels.” “There is a lot of competition for people to work. It’s not just about how much salary they are going to make — it’s about the work environment, the ability for stability. We want to make sure our employees have the best environment to work in,” Morrow added. Similarities “One of the reasons I believe why Daldrop chose this area, Phoenix in particular, is because it is a village, a river-based village. Neckartailfingen in Germany where Daldrop is based is also a river-based village, manufacturing community. So, there is a lot of similarities — that smalltown feel,” Morrow said. “We have a lot of connections through multiple employees that lead back to Carrier, also. Everything came together, the timing everything.” “We are thankful for all the economic development support. Everyone has been helping make this happen. So, keep it up, it is working, that is all I got to say, Sullivan said. “If you look at historical industrial manufacturing, this region has skills that have been un-utilized. The northern industrial region has a lot of skills that if we can tap before they go away, we can leverage them. That is what we are trying to do. You’d be surprised at the supply chain left behind from Carrier — that supply chain is still there.” “Operation Oswego County has been fantastic,” Morrow added. “I can’t say enough good things about that group.” What Is Cleanroom Technology Cleanroom technology is a system of specialized engineering, filtration and operational controls used to maintain an extremely low concentration of airborne particles, microbes and chemical vapors. How It Works • Air Filtration: Uses HEPA or ULPA filters to remove 99.97% of tiny particles down to 0.3 microns. • Airflow Control: Directs air in a steady, unidirectional (laminar) or filtered turbulent pattern to push dust away from work areas. • Environmental Regulation: Maintains precise control over temperature, humidity and positive air pressure to block outside air leaks. • Specialized Attire: Requires personnel to wear full-body garments (“bunny suits”), gloves and masks to stop human shedding
Alnylam bulls and bears fight it out after business-shaking guidance cut
While Alnylam’s recent reduced revenue guidance spooked investors, analysts remain broadly bullish on the biotech’s commercial prospects.
Future African Scientist, Two Years On: From Training Scientists to Building Africa's Biotech Companies
Martin Lubowa and Daniel Zhang on how Future African Scientist grew from a research bootcamp into the FAS Biocamp, a program turning Africa’s scientists into founders of real biotech companies. Two years ago, the Ragon had the opportunity to speak with two alumni of MIT’s Evolution of an Epidemic course, Martin Lubowa and Daniel Zhang. […]
Firm Advises Oxford Science Enterprises on IP Matters Related Sensible’s $47 Million Financing
On October 6, 2026, Sensible Biotechnologies (Sensible), a biotechnology company developing a first-of-its-kind platform for naturally modified mRNA medicines, announced that it has secured $47…
TikTok CEO Sees AI Breakthroughs in 3 Years [2026]
TikTok CEO Shou Zi Chew says AI could drive major physics and biotech breakthroughs within two to three years, per CNBC.
DOE, NIH, and Biohub Partner to Build Foundational Data for Predictive Biological AI Models
WASHINGTON and SAN FRANCISCO, Oct. 9, 2026 — The Department of Energy’s (DOE) Office of Science, the National Institutes of Health (NIH), and Biohub signed a Memorandum of Understanding (MOU) to advance the frontier of Artificial Intelligence (AI) in biology, deepen our understanding of human health and disease, and accelerate breakthroughs in medicine and biotechnology. […]
Northwest Biotherapeutics and the UK National Health Service Blood and Transplant Announce Collaboration to Support DCVax®-L Production
/PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for...
All Roads Lead to Texas: 15th Annual Texas Life Science Forum to Bring Together Biotech’s Builders and Backers on Nov. 10 in Houston
The Rice Alliance for Technology and Entrepreneurship and BioHouston today announced that the 15th Annual Texas Life Science Forum is set for Tuesday, Nov. 1...
GenScript Launches Life Sciences Startup PitchFest with NVIDIA to Accelerate Biotech Innovation
/PRNewswire/ -- GenScript Biotech Corporation today announced the GenScript and NVIDIA Life Sciences Startup PitchFest, a global competition for startups...
Valerio Therapeutics Provides an Update on Its Business and Presents Its Financial Results for the First Half of 2026
VILLEJUIF, France, October 07, 2026--Regulatory News: Valerio Therapeutics (FR0010095596 - ALVIO), a pioneering biotechnology company in the field of next-generation precision therapies ("Valerio", or the "Company"), provides an update on its operations and presents its financial results for the half-year ended 30 June 2026.
Northwest Biotherapeutics Announces Keynote Presentation on Harnessing Immunity: A Personalized, Multi-Target Approach to Cancer At the UK National Health Service Annual Oncology Conference
/PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for...
In Shanghai’s ‘Science City,’ China’s ascendant biotechs make their pitch to the world
For two years, American labs and board rooms have been riven with excitement and anxiety over the vertiginous rise of Chinese biotech.
Not All Magnesium Supplements Are Equal: What Science Says About Absorption
Magnesium has quietly become one of the most talked-about minerals in nutrition science, and a new narrative review published in Food Science and Biotechnology by Sanem Gultekin and Merve Tomas of Istanbul Technical University explains why the supplement aisle may be far more
Studying Science in an Anti-Scientific Time
This Chronicle Review Deep Cut was first published in 2025. By Julianne Werlin Thanks for reading The Chronicle Review! Subscribe for free to receive new posts and support my work. Subscribe The last two decades have not been kind to science studies. Already bruised and battered by the “science wars” of the 1990s, by the 2000s sociologists of science — who had long argued that science had to be understood in its human context — were encountering the funhouse-mirror version of their own views in right-wing critiques of climate scientists. It was enough to give some prominent scholars pause. “Was I wrong to participate in the invention of this field known as science studies?” asked Bruno Latour, the most famous sociologist of science in the world, in 2003. “Should we apologize for having been wrong all along? Or should we rather bring the sword of criticism to criticism itself and do a bit of soul-searching here: What were we really after when we were so intent on showing the social construction of scientific facts?” In response, Latour proposed a change of method and attitude. Science studies, now chastened and contrite, would no longer seek to strip facts of their authority, but to enrich and enhance them. What this meant in practice was never fully clear. But his diagnosis of problems resonated, even if his solutions did not. Latour’s exercise in public hand-wringing signaled a shift in mood. By 2016, with the first election of Donald Trump, the idea that skepticism of science was a right-wing position, not a left-wing one, had become a commonplace, discussed eagerly in The New York Times. For liberals, vaccine denial during the Covid era and Trump’s second-term attacks on the funding of scientific research, covered extensively in these pages, added a new urgency to the defense of science on both practical and principled grounds. There was little appetite for a sociology or philosophy of science that emphasized the messiness and missteps of the scientific process rather than its integrity and triumphs. The distinguished historian of science Peter Dear’s new book, The World as We Know It: From Natural Philosophy to Modern Science (Princeton University Press, 2025), which seeks to tell the story of 18th- and 19th-century science for a general public, may seem comfortably remote from these bitter contests. In its 16 short chapters, Dear draws swift, sure sketches of major discoveries from Newton to Einstein, ably guiding the reader through debates on stellar nebulae, animal taxonomy, atomic chemistry, evolution, and other flashpoints in the history of science. But though a work of history, Dear’s book must still negotiate our polarized present. In a blurb on its back cover, the historian of biology Lynn K. Nyhart alludes to the “present moment, when scientific knowledge is being swamped by misinformation and its institutions are under siege.” Dear himself, in his conclusion, refers to the “yard signs” and “bumper stickers” that proclaim “Science Is Real.” One antidote to both anti-science propaganda and to reductive slogans in science’s defense is a robust history and philosophy of science: exactly what Dear’s scholarship has long offered. But his new book illustrates how difficult such work has become. Dear, an emeritus professor of history at Cornell University, is best known as a creative and philosophically minded historian of the Scientific Revolution. His edited volume The Literary Structure of Scientific Argument (1991) analyzed the rhetoric of Galileo’s thought experiments to brilliant effect. Discipline and Experience: The Mathematical Way in the Scientific Revolution (1995) was a major contribution to the analysis of scientific experiments in early modern Europe and beyond, while Revolutionizing the Sciences: European Knowledge in Transition, 1500-1700 (2001), now in its third edition, remains one of the best overviews of the profound epistemological upheavals of 16th- and 17th-century science. But Dear has also ventured into later periods. Nearly two decades ago, in The Intelligibility of Nature: How Science Makes Sense of the World (2006), he turned to the 18th and 19th centuries to sketch a history and theory of scientific knowledge. Aimed at a generalist audience, Dear’s simple prose belied serious philosophical ambitions. Science, Dear argued, has two aspects: “natural philosophy,” the quest to understand the true nature of the universe, and “instrumentality,” the applied skills and technologies that allow us to manipulate the world for human advantage. Both strands are ancient, but the innovation of the phenomenon we call “science” was to yoke them together. As Francis Bacon wrote, “Human knowledge and human power meet in one; for where the cause is not known, the effect cannot be produced,” an insight typically abridged to “knowledge is power.” Or, in Bertrand Russell’s characteristically blunt phrase, science has two functions, “1. to enable us to know things, and 2., to enable us to do things.” So far, so conventional. But Dear took issue with this familiar story in one respect. Bacon’s formula implied that theory and practice could be fused in a single method. In fact, Dear argued, the quest to understand nature and the desire to manipulate it were coupled only loosely. They could come together, but they could also pull apart. Focusing on natural philosophy, the “knowing” half of the scientific circle, he used a series of case studies from cosmology, taxonomy, chemistry, electromagnetism, and quantum theory to show how theories changed over time, in dialogue with practice, but never reducible to it. Take the case of matter, the basic substrate of the physical world. In the 18th and 19th centuries, scientists not only disagreed about what it was, but also about how well it could be known. In 1789, the chemist Antoine Lavoisier dismissed speculation about the atomic composition of chemicals as “discussions entirely of a metaphysical nature,” as he sought to orient chemistry away from philosophical abstraction and toward laboratory results. But in the 19th century, atoms returned with a vengeance in the atomic chemistry of John Dalton, who wanted to explain the underlying structure of nature. It was not just that Dalton and Lavoisier had a different set of experimental results, or even a different theory, Dear showed. What counted as an explanation had changed. In arguing that scientific theories depended on their intelligibility to human beings with complex arrays of beliefs and commitments, Dear was in sympathy with science studies. Key figures such as the sociologist Steven Shapin emphasized the importance of psychological mechanisms like trust in the formation and acceptance of scientific ideas. But in focusing on the scientific pursuit of knowledge, not its politics or economics, Dear resisted the more cynical perspective of some of his colleagues. The Intelligibility of Nature strikes a very different note than Shapin’s collection of a few years later, Never Pure: Historical Studies of Science as If It Was Produced by People With Bodies, Situated in Time, Space, Culture, and Society, and Struggling for Credibility and Authority (2010), to name just one example. Walking a very fine line, Dear depicted science as driven at once by complex social dynamics and by the intellectual power of real discoveries. It was a testament not only to his own acumen but also to the vitality of the field that he was able to do so. Nearly two decades later, The World as We Know It returns to the questions broached in The Intelligibility of Nature. Like Dear’s earlier study, it begins with the Newtonian cosmos and ends with debates between Einstein and Bohr on quantum physics. Beyond its terminal figures, many of the same characters appear in both studies, including the naturalists John Ray and the Comte de Buffon; the chemists Étienne François Geoffroy, Antoine Lavoisier, and John Dalton; as well as Charles Darwin and Michael Faraday, among others. Its subject is nearly identical: As in The Intelligibility of Nature, The World as We Know It considers natural philosophy as opposed to instrumentality, here defined as the “desire to create a picture of what the world is really like — the world as God knows it — rather than simply having instrumental or operational control over it.” The two books also overlap in insights — and sometimes even in language. The reader who has learned in The Intelligibility of Nature that Buffon’s method of classifying animals “reflected his belief in the importance of the senses and empiricism in learning about nature (a doctrine associated with Newton and the philosopher John Locke)” will experience a sense of déjà vu on reading, in The World as We Know It, that the classification “reflects Buffon’s commitment to the epistemological stance of Newton and his philosophical underlaborer John Locke, who stressed the role of the senses in creating natural knowledge.” Later in the passage, we read that, “because of its stress on understanding the ways of life of animals in their environments, Buffon’s approach could almost be labeled (anachronistically) as ‘ecological.’” And again, “an anachronistic way of putting it would be to say that Buffon recommends an ecological mode of understanding.” Likewise, in The Intelligibility of Nature we read of Dalton that he was initially drawn to meteorology, and that: He did a bit of experimental work on these things, especially having to do with the water-holding capacity of gases, but his real interest lay in understanding what, at an underlying natural-philosophical level, was really going on physically.” Whereas, in The World as We Know It: He did experimental work on these things, especially concerning the water-holding capacity of gases — although not at a very refined level quantitatively — but he was continually trying to develop a theoretical conception of what was happening physically. The final full chapter of each book closes on the same resigned note. Intelligibility: These days, most serious work on the natural philosophical underpinnings and implications of quantum mechanics is performed not by physicists but by philosophers of science. Among scientific practitioners themselves, Bohr’s attempt to use instrumentality as sufficient grounds for a respectable science has met with a high degree of success. And again, in The World as We Know It: Bohr’s and Einstein’s concerns are now questions that are mostly discussed by philosophers of science rather than by physicists themselves. The marginalization of these sorts of questions amounts to the demise of natural philosophy, at least in physics, in the 20th century. Quantum mechanics “works,” and that’s good enough for most scientists who encounter it. Examples could be multiplied. When handling the same subject matter, some echoes are inevitable. Scholars should not feel that because they have written “Isaac Newton died in 1727” in one book, in the next they must describe him as perishing, expiring, or meeting his maker. But the repetitions of language and arguments (not to mention six reproduced images) threaded throughout The World as We Know It are more extensive than that. They should have been caught by Princeton University Press or its reviewers, and revised. Because the two books have so much in common, it is easy to see where they diverge. The World as We Know It is a less theoretical work than its predecessor. The sociology of knowledge that organized The Intelligibility of Nature has been reduced in scale and folded into readings and examples. The taut interplay between history and theory, which gave the earlier study so much interest, is there, but it is subtle. In the earlier book, the case studies demonstrated theoretical claims about the character and development of science. In the later work, each narrative of discovery is an end in itself. Insights emerge from the history, but they do not control the organization of the study. With the theory muted, it can be hard to understand the logic uniting Dear’s sprawling history of more than two centuries of scientific knowledge. The 16 brisk chapters cover an enormous amount of material. But the closer the volume edges to comprehensiveness, the more obvious the missing elements become. A chapter on “Institutions and Pedagogy,” describing the birth of the research university, illustrates the problem. Inserted roughly halfway through the book, the unnumbered chapter is designed as an “entr’acte,” in acknowledgement that it does not fit the study’s organization around scientific discoveries. Yet as Dear is well aware, no general history of the development of modern science can bracket its 19th-century institutionalization and professionalization. It was the 19th-century university, after all, that gave us the “scientist,” a term coined by the Cambridge philosopher William Whewell. Dear’s history of scientific discoveries implies a wider social and institutional history, but it remains largely subterranean, only occasionally extruded under the pressure of the narrative. It must be said that the balance is not all on the side of the earlier study. There are some advantages to the more historical, less theoretical organization of The World as We Know It. Dear’s accounts of paradigm shifts are remarkably lucid, no small accomplishment given that they span fields and centuries. He makes excellent use of the wealth of new scholarship on Darwin and his influences, to which he has himself contributed. It is satisfying to see puzzle pieces from Buffon’s natural history, Georges Cuvier’s animal taxonomy, Thomas Robert Malthus’s demography, and Charles Lyell’s geology recombined seamlessly in the Darwinian jigsaw. Likewise, Dear’s discussion of stellar nebulae, divided between chapters two and 15, shows vividly how Newton, Kant, Herschel, and Hubble reimagined insights and observations as they sought to discover whether the diffuse light that filtered through early telescopes was a glowing, gaseous substance or discrete but distant stars. Yet despite such pleasures, the book remains a more modest work than The Intelligibility of Nature. Dear has clearly not changed his views about the history of science. But in the two decades that have elapsed, the discipline and the world around it have changed, making it harder to write a sociologically and philosophically ambitious history of science for the general reader. That is a shame, because in the age of Silicon Valley and biotechnology, both the reciprocity and the tensions Dear identified between the epistemological and instrumental ambitions of science are more evident than ever. In recent years, some of the most exciting new books on the history of science in early modernity have focused precisely on this pressure point. Important studies such as Pamela H. Smith’s From Lived Experience to the Written Word (2022), James Poskett’s Horizons: The Global Origins of Modern Science (2022), and Vera Keller’s The Interlopers: Early Stuart Projects and the Undisciplining of Knowledge (2023) all shed new light on how early modern science negotiated the relationship between its instrumental and epistemological ambitions, or in Russell’s phrase, knowing and doing. There is every opportunity for a philosophically informed approach to draw new insights from this wealth of material. Dear, unfortunately, has not done so in The World as We Know It. But for future scholars of the history of science, his body of work over nearly four decades may provide just the model. Julianne Werlin is an associate professor of English at Duke University. Thanks for reading The Chronicle Review! Subscribe for free to receive new posts and support my work. Subscribe
How Biotech AI And Robotics Bridge Bottlenecks To Impact Global Health
While biotech increasingly adopts AI for R&D, manufacturing bottlenecks constrain health innovation. AI and robotics have the potential to unlock health impact globally.
Xtalks Announces its Life Science Webinar Calendar for October 2026
Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical device and food industries. Access to all webinars is free, so be sure to register today to save your place! Participate in the discussion and stay relevant in your field!
Xtalks Announces its Life Science Webinar Calendar for October 2026
/PRNewswire/ -- Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical device and food industries....
In Shanghai's 'Science City,' China's ascendant biotechs make their pitch to the world
A small conference with big ambitions mirrors the rapid growth of Chinese biotech, invites comparisons to U.S. biotech gathering also known for deal-making.
UNR launches animal science program to keep students in-state
University of Nevada, Reno launches a new bachelor's degree in animal science to train students for livestock and biotech careers.
Good Science Is Not Enough: K4-MST To Explore At US BioTech Day, What Makes a Biotech Company Investable
An expert panel will examine why promising science is not enough and what biotech companies must prove to become financeable.
Good Science Is Not Enough: K4-MST To Explore At US BioTech Day, What Makes a Biotech Company Investable
An expert panel will examine why promising science is not enough and what biotech companies must prove to become financeable.
The longevity boom is getting ahead of the science
Billions are pouring into anti-ageing biotech, but manipulating ageing has risks we are only beginning to understand.
NeuroSense Provides Business Update and Progress for the First Half of 2026
/PRNewswire/ -- Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company focused on developing...
Pioneer of China NewCo model sued in US over trade secret misuse, double-dealing
A legal feud unfolding in New York is putting a spotlight on the work of a business development veteran who is credited for pioneering one of biopharma’s hottest dealmaking mechanism: the China “NewCo” model. In a lawsuit originally filed in New York state court and recently moved to federal court, China’s Lepu Medical Technology has alleged that biopharma business development consultant Su Zhang, who was hired to help shop its GLP-1 weight-loss candidates to Western partners, engaged in corporate double-dealing and trade secret leaks. According to the complaint, while acting as Lepu’s primary dealmaking liaison for a group of obesity and metabolic disease drug candidates, Zhang was secretly double-dipping as the acting chief business officer for a direct competitor, BrightGene Pharmaceutical. “She never adequately disclosed the role, never sought Lepu’s consent, and never proposed any safeguard,” Lepu alleged in its complaint, which was filed in July after Zhang’s consulting firm, CoDevCo, sought certain transaction-based success fees from its angry customer through an arbitration process in Singapore. Lepu, the parent company of Lepu Biopharma, has asked Zhang to pay back its $500,000 retainer and disgorge all benefits she received during the alleged breaches of fiduciary duty, plus other damages and relief. The company has also requested the court grant injunctions to protect Lepu’s trade secrets. The ill-fated partnership officially kicked off in December 2024, when Lepu tapped CoDevCo as its “exclusive business development mechanism” to identify collaborators for the company’s drug candidates. According to Lepu’s complaint, Zhang personally negotiated and signed the agreement as managing director for CoDevCo, which used her home address. Before the Lepu deal, Zhang made a name following a short stint as the global head of business development for Hengrui Pharmaceuticals. It was during her tenure that Hengrui signed a landmark deal granting exclusive rights for a portfolio of GLP-1 assets to Hercules, which was at that time newly established by a group of private equity and venture capital firms. In addition to the regular upfront and milestone payments, Hengrui also gained an equity stake in Hercules, which later became Kailera Therapeutics. The Hengrui-Hercules deal opened a new paradigm, where a Chinese biopharma company spins off certain early-stage assets to investors for further development through the creation of a new company abroad. The “NewCo” model quickly came into vogue as it allows Western investors to access high-potential assets originating from China at an early stage while giving the Chinese licensors an opportunity to reap long-term benefits through equity stakes in the new firms. The NewCo model proved its value when Kailera staged a record-breaking $625 million IPO on Nasdaq this April, merely two years into the Hengrui deal. Related Kailera CEO 'knew we were in a good spot' before obesity biotech's record-breaking $625M IPO On her LinkedIn page, Zhang described her work at Hengrui as “[b]uilding team and capability from the ground up,” forming NewCo and major pharma partnerships worth billions of dollars. Lepu clearly wanted that kind of track record to help boost its own cardiometabolic portfolio, which includes a range of assets for obesity, Type 2 diabetes, fatty liver disease and muscle preservation during weight loss treatment. “Lepu’s pipeline is very valuable, but only if Lepu could secure the right international partner to expand into the overseas market during the available commercial window,” the company argued in its complaint. The Chinese biotech said it had little knowledge of U.S. laws, customs or business practices in the business development field, and therefore “needed to rely entirely” on the expertise of Zhang and her team as the firm’s first engagement of a U.S.-based BD consultant. “Zhang’s dominating influence on the business development strategy is further evidenced by the fact that she personally controlled the business-development communications on behalf of Lepu with potential partners,” Lepu said in its complaint. After entering the deal, Zhang introduced Lepu to her four associates. According to Lepu’s version of events, all of them were allegedly employed at different time points to perform similar jobs at other Chinese companies that Lepu described as its competitors, while having access to Lepu’s confidential information. As such, Lepu described Zhang’s team as “a roster of individuals whose primary professional loyalty, by virtue of their concurrent full-time employment, ran to Lepu’s competitors.” As well as the specific examples set out in the case, a look at Lepu’s deals over the period suggests Zhang may have been involved in at least one transaction. During their partnership, Lepu, through its subsidiary Shanghai Minwei Biotechnology, also out-licensed its GLP-1/GIP/FGF21 agonist MWN105 to a NewCo called Sidera Bio in the fall of 2025. The deal included an upfront and near-term payment of $35 million, up to $1.01 billion in milestones, and a 9.99% stake in the Danish startup. It seems likely that Zhang facilitated the Minwei deal given that Lepu is on record as having used CoDevCo as its “exclusive business development mechanism.” The big shock for Lepu came in the form of a news article on June 25, 2025. The article, reporting on phase 2 data for BrightGene’s GLP-1/GIP receptor agonist BGM0504, identified Zhang as acting chief business officer of the Lepu rival. Blindsided by her association with BrightGene, Lepu confronted Zhang in July 2025. “Lepu was given assurances that there was nothing to be concerned about and told that Zhang would explain the matter to Lepu,” Lepu alleged in its complaint. “Zhang never did.” Lepu claimed that Zhang had the motive and opportunity to steer potential prospective partners toward BrightGene or other competitors. Later, in February 2026, one of Zhang’s associates joined BrightGene as the vice president for global business development, according to the complaint. Around the same time, Lepu sent written demand letters asking Zhang to account for her BrightGene role, identify what confidential data were shared with the rival firm, and provide any conflict-of-interest or firewall policies during the engagement. According to Lepu, neither CoDevCo nor Zhang answered the questions in their responses. Related Novo vs. KBP: How a $1.3B deal turned into a fraud accusation and an international legal fight In a motion to dismiss filed with the U.S. District Court in the Eastern District of New York on Sept. 4, Zhang’s legal team argued that Lepu’s agreement was signed with CoDevCo, and that an employee of the contractor does not owe fiduciary duties to the client. In its complaint, Lepu said: “That CoDevCo was the contracting entity does not insulate Zhang from personal liability for duties she personally undertook and personally breached.” Taking the argument one step further, the defending party argued that the consulting agreement “does not create a fiduciary relationship even between CoDevCo and Lepu; instead, it identifies CoDevCo as an independent contractor retained to market Lepu’s business to potential western partners.” Although CoDevCo was Lepu’s exclusive business-development contractor, there were no terms stipulating that the consulting firm should serve only Lepu, Zhang’s lawyer noted. As to Lepu’s claims that Zhang misappropriated trade secrets, the defendant argued that Lepu authorized the use of the information so Zhang’s team could perform their service per the agreement. In a rebuttal filed on Sept. 11, Lepu’s lawyer set out why they believe the Chinese biotech satisfied New York law’s misappropriation definition by alleging that the defendant used a trade secret “in breach of a duty or through improper means.” As an alternative to dismissing the suit, the defendant suggested the action should be stayed pending outcomes from the arbitration of a separate case in Singapore. While NewCo pioneer Zhang is defending her business arrangements, momentum behind the NewCo trend has continued unabated into 2026. Through August, Chinese biotech assets have spurred 15 NewCo deals this year, according to local trade publication PharmaDJ.
China is excelling in health tech. That’s good news for the world
Ruby Wang, a physician and biotech consultant in the U.K., on her upcoming book on the emergence of China as a global health superpower.
Why do we get sleepy? Uncovering the science of sleep drive
Why do we get sleepy? A new preclinical study sheds some light on the science of sleep drive.
life – the bioRN Life Science Cluster magazine
Alliances for success – Heidelberg and the Rhine-Neckar region are among the most dynamic life science ecosystems in Europe.
Merck Life Science Expands Bengaluru Manufacturing with €13 Million Investment
Merck Life Science is expanding its manufacturing capabilities in Bengaluru with an investment of approximately €13 million, strengthening the company’s ability to supply critical materials to customers across India and the wider Asia-Pacific region. The expansion at Merck Life Science’s Jigani site in Bengaluru will introduce biological buffer manufacturing alongside the facility’s established chemistry capabilities. The investment is designed to enable faster and more reliable access to critical materials used by customers across research, diagnostics, biotechnology and biopharmaceutical manufacturing. The development further advances Merck Life Science’s “in-region, for-region” approach, under which the company is expanding manufacturing capabilities closer to the markets and customers it serves. By adding biological buffer production in India, the Jigani expansion will broaden the site’s manufacturing capabilities while strengthening Merck Life Science’s regional supply infrastructure for the rapidly developing life sciences sector across India and Asia-Pacific. The company said the expansion reflects both the contribution of its teams and its collaboration with government and industry stakeholders. Merck Life Science acknowledged the support of India’s Department for Promotion of Industry and Internal Trade (DPIIT), the German Embassy New Delhi, and Invest India in helping strengthen life science manufacturing capabilities in the region. The investment comes as India continues to expand its role across pharmaceutical, biotechnology, diagnostics and biomanufacturing value chains, increasing demand for dependable regional access to materials supporting research and manufacturing operations. The Bengaluru expansion reinforces Merck Life Science’s focus on building manufacturing capacity within Asia-Pacific and supporting customers through a more regionalised supply network.
How Biotechnology Could Protect the Crops We Depend On
Crop biotechnology could protect vital food crops from disease, pests and climate stress, with bananas showing the potential of modern tools.
Europe has the science. Now it needs a clinical trials system to match.
Europe has the scientific expertise to lead the next generation of cancer research, but slow and fragmented clinical trial processes, particularly in the case of multinational trials, are not allowing it to reach its full potential. The EU Biotech Act can address the existing bottlenecks to turn this excellence into faster research, stronger competitiveness and earlier opportunities for patients.
‘High tide’ of China biotech deals seen as US curb fears fade: analysts
Stocks jump on reports Washington will allow most licensing deals under ‘substantially softer stance’ than had been feared, analysts say.
BioTech Social Announces Advisory Board To Advance Financial Innovation For Life Science Companies
× This page requires Javascript. Javascript is required for you to be able to read premium content. Please enable it in your browser settings. kAm k^Am kAm k^AmkAm k^AmkAm k^AmkAm k^AmkAmk6>mtIA6C:6?465 =6256CD 24C@DD 3:@E649?@=@8J[ 7:?2?46[ E649?@=@8J[ A2E:6?E 6?8286>6?E[ 4@>>F?:42E:@?D[ 2?5 4@>A2?J 3F:=5:?8 H:== 25G:D6 q$x 2D :E 3F:=5D 7:?2?4:2= :?7C2DECF4EFC6 2C@F?5 =:76 D4:6?46 :??@G2E:@?k^6>mk^AmkAmqt%wt$sp[ |5][ $6AE6>36C `f[ a_ae \ , k2 9C67lQ9EEAi^^^?6HDC@@>^Q C6=lQ?@@A6?6CQmz~#t(x#tk^2m . q:@%649 $@4:2= x?4] Wq$xX[ A2C6?E 4@>A2?J @7 q:@%649 uF?5:?8 !@CE2=[ E@52J 2??@F?465 E96 7@C>2E:@? @7 2? 25G:D@CJ 3@2C5 3C:?8:?8 E@86E96C 6IA6C:6?465 =6256CD 7C@> 3:@E649?@=@8J[ 962=E942C6[ 7:?2?46[ E649?@=@8J[ A2E:6?E 25G@424J[ 4@>>F?:42E:@?D[ 2?5 4@>A2?J 3F:=5:?8]k^AmkAm%96 25G:D@CJ 3@2C5 H:== DFAA@CE q$x’D 3C@256C >:DD:@? @7 255C6DD:?8 @?6 @7 E96 >@DE A6CD:DE6?E 492==6?86D :? =:76 D4:6?46Di 4@??64E:?8 AC@>:D:?8 :??@G2E:@? H:E9 E96 42A:E2= ?66565 E@ 25G2?46 E9C@F89 =6?8E9J 2?5 6IA6?D:G6 56G6=@A>6?E A2E9H2JD]k^AmkAmq$x :D 3F:=5:?8 7:?2?4:2= :?7C2DECF4EFC6 2C@F?5 =:76 D4:6?46 :??@G2E:@?] q:@%649 uF?5:?8 !@CE2=[ :ED $tr\C68:DE6C65 2?5 ux}#p\>6>36C #68F=2E:@? rC@H57F?5:?8 A@CE2=[ C6AC6D6?ED E96 4@>A2?J’D 7:CDE :>A=6>6?E2E:@? @7 E92E DEC2E68J] ~G6C E:>6[ q$x :?E6?5D E@ 6IA=@C6 255:E:@?2= 7:?2?4:2= DECF4EFC6D[ E@@=D[ 2?5 G69:4=6D 56D:8?65 2C@F?5 E96 5:DE:?4E:G6 42A:E2= ?665D @7 =:76 D4:6?46 4@>A2?:6D]k^AmkAm“$4:6?E:DED DA6?5 J62CD 56G6=@A:?8 D@=FE:@?D 7@C 5:D62D6D 7@C H9:49 A2E:6?ED DE:== 92G6 E@@ 76H @AE:@?D[ @?=J E@ D66 E96> 72:= 5F6 E@ 7F?5:?8 82AD 2E E96 EC2?D:E:@? :?E@ 4=:?:42= 56G6=@A>6?E” D2:5 sC] }6G2 (6DE[ rt~ 2?5 r@\u@F?56C @7 q$x] “p5G2?4:?8 E92E C6D62C49 C6BF:C6D DFDE2:?65 DFAA@CE @G6C >2?J J62CD] (6 H2?E E@ 96=A 4C62E6 2? 6?G:C@?>6?E :? H9:49 AC@>:D:?8 4=:?:42= D4:6?46[ >66E:?8 ECF6 F?>6E ?665D[ 42? 4@?E:?F6 >@G:?8 7@CH2C5 H9:=6 >F?:E:6D 27764E65 3J E96 5:D62D6 46?EC2= E@ E96 4@?G6CD2E:@?]”k^AmkAmp55C6DD:?8 E96 {:76 $4:6?46 “'2==6J @7 s62E9”k^AmkAm%96 7:?2?4:?8 492==6?86 :D A2CE:4F=2C=J 24FE6 5FC:?8 E96 D@\42==65 7F?5:?8 “G2==6J @7 562E9”[ E96 A6C:@5 :? H9:49 4@>A2?:6D >FDE 4@?E:?F6 :?G6DE:?8 :? C6D62C49[ 4=:?:42= 56G6=@A>6?E[ C68F=2E@CJ H@CA2?J 3F:=5:?8[ @7E6? 367@C6 E96J 42? 86?6C2E6 >62?:?87F= 4@>>6C4:2= C6G6?F6 @C 2EEC24E EC25:E:@?2= :?DE:EFE:@?2= 42A:E2=]k^AmkAmq$x =2F?4965 q:@%649 uF?5:?8 !@CE2= :? yF?6 a_ae 2D 2 C68F=2E65 :?G6DE>6?E 4C@H57F?5:?8 A@CE2= 3F:=E DA64:7:42==J 7@C =:76 D4:6?46 4@>A2?:6D] %96 A@CE2= 6?23=6D 6=:8:3=6 4@>A2?:6D E@ C2:D6 FA E@ Sd >:==:@? :? 42A:E2= 2??F2==J 7C@> :?5:G:5F2= :?G6DE@CD F?56C #68F=2E:@? rC@H57F?5:?8 H9:=6 4C62E:?8 @AA@CEF?:E:6D 7@C 2 3C@256C A@AF=2E:@? @7 :?G6DE@CD E@ A2CE:4:A2E6 :? AC:G2E6 =:76 D4:6?46 :??@G2E:@?]k^AmkAmq$x G:6HD E96 A@CE2= 2D E96 368:??:?8 @7 2 =2C86C 677@CE]k^AmkAm“q:@%649 uF?5:?8 !@CE2= :D @FC 7:CDE :>A=6>6?E2E:@?[ ?@E E96 6?5A@:?E[” D2:5 qC:2? !] r9C:DE:6[ r92:C 2?5 r@\u@F?56C @7 q:@%649 $@4:2= x?4] “~FC 3C@256C @3;64E:G6 :D E@ 3F:=5 7:?2?4:2= :?7C2DECF4EFC6 2C@F?5 E96 D4:6?46[ 56G6=@A:?8 7:?2?4:?8 >6492?:D>D E92E 36EE6C >2E49 42A:E2= E@ E96 >:=6DE@?6D[ C:D6?E]”k^AmkAmr9C:DE:6 25565[ “rC@DD:?8 E96 G2==6J @7 562E9 :D ?@E D:>A=J 2 7F?5C2:D:?8 AC@3=6>] %96 42A:E2= 92D E@ H@C< H:E9:? 2 >F49 =2C86C DJDE6> :?G@=G:?8 D4:6?E:7:4 >:=6DE@?6D[ C68F=2E@CJ A2E9H2JD[ A2E:6?ED[ DEC2E68:4 A2CE?6CD[ 4@>A2?J =6256CD9:A[ 2?5 :?G6DE@C 6IA64E2E:@?D] %92E :D @?6 C62D@? H6 H2?E65 2? 25G:D@CJ 3@2C5 H:E9 DF49 2 H:56 C2?86 @7 6IA6C:6?46]”k^AmkAmp |F=E:5:D4:A=:?2CJ p5G:D@CJ q@2C5k^AmkAm%96 25G:D@CJ 3@2C5 3C:?8D E@86E96C =6256CD H9@ 92G6 3F:=E 2?5 7:?2?465 4@>A2?:6D[ 56G6=@A65 3:@E649?@=@8J A2CE?6CD9:AD[ ?2G:82E65 C68F=2E65 >2CF?:E:6D[ >2?2865 4@CA@C2E6 C6AFE2E:@?[ 2?5 2DD6>3=65 =6256CD9:A E62>D]k^AmkAm%96 8C@FA :?4=F56D sC] x>25 p;;2H:[ q@3 q2C:49[ y@9? r@FC:4[ z2C:? w6==DG:6?6?4:2 ~CE:K[ (:==:2> $49C256C[ 2?5 p?5C6H (:==:D]k^AmkAmsC] x>25 p;;2H:[ p5G:D@C[ :D rt~ 2?5 r@\u@F?56C @7 #J3@sJ?[ 2 3:@E649?@=@8J 4@>A2?J 56G6=@A:?8 42?46C :>>F?@E96C2A:6D E2C86E:?8 2 4CJAE:4 AC@E6@>6] !C6G:@FD=J[ 96 H2D ':46 !C6D:56?E @7 qFD:?6DD s6G6=@A>6?E 2E p3D4:[ H96C6 96 5C@G6 >@C6 E92? Se__ >:==:@? :? A2CE?6CD9:AD 2?5 A=2J65 2 C@=6 :? E96 4@>A2?J’D S`]d 3:==:@? x!~] w6 2=D@ 4@\7@F?565 px\5C:G6? AC@E6:? 56D:8? 4@>A2?J s6?@G:F>[ H9:49 H2D 24BF:C65 3J p3D4:] p;;2H: 9@=5D 2 !9s :? q:@496>:DECJ 2?5 |@=64F=2C q:@=@8J 2?5 2? |qp 7C@> E96 #25J $49@@= @7 |2?286>6?E 2E &r $2? s:68@]k^AmkAmq@3 q2C:49[ p5G:D@C[ :D 2? 6I64FE:G6 D62C49 AC@76DD:@?2= H:E9 >@C6 E92? ae J62CD @7 6IA6C:6?46 C64CF:E:?8 4@>>F?:42E:@?D[ AF3=:4 C6=2E:@?D[ :?G6DE@C C6=2E:@?D 2?5 8@G6C?>6?E 2772:CD =6256CD] %9C@F89 r}# $62C49[ 96 H@C =6256CD9:A ?665D] w:D 6IA6C:6?46 DA2?D &]$] 2?5 :?E6C?2E:@?2= >2C246FE:42= 2?5 962=E942C6 4@>>F?:42E:@?D[ 4@?DF>6C AC@5F4ED 2?5 7:?2?4:2= D6CG:46D]k^AmkAmy@9? r@FC:4[ p5G:D@C[ 3C:?8D >@C6 E92? 7@FC 564256D @7 6IA6C:6?46 24C@DD 7:?2?46[ 32?@?E@CJ x?E6C7:?2?4:2= }6EH@C 7C@> :ED 62C=J J62CD E9C@F89 :ED 8C@HE9 :?E@ 2 7:?2?4:2= D6CG:46D ?6EH@C< DFAA@CE:?8 E9@FD2?5D @7 :?DE:EFE:@?D ?2E:@?H:56] t2C=:6C[ 96 96=5 =6256CD9:A A@D:E:@?D 2E !$x}6E 2?5 q6== pE=2?E:4[ ?@H '6C:K@? 2?5 AC6G:@FD=J H@C>:DD:@? W$trX] w6 9@=5D 2? |qp 7C@> %96 v6@C86 (2D9:?8E@? &?:G6CD:EJ 2?5 2 q$ :? r@>>6C46 7C@> E96 &?:G6CD:EJ @7 ':C8:?:2]k^AmkAmz2C:? w6==DG:D] (:==:D D6CG6D @? E96 w62=E942C6 2?5 !92C>246FE:42= |2?286>6?E !C@8C2> p5G:D@CJ q@2C5 2E r@=F>3:2 qFD:?6DD $49@@= 2?5 E96 q@2C5 @7 p5G:D@CD 2E v6@C86E@H? &?:G6CD:EJ’D |4s@?@F89 $49@@= @7 qFD:?6DD] w6 62C?65 2 q$qp 7C@> v6@C86E@H? &?:G6CD:EJ 2?5 2 ys 2?5 |qp 7C@> r@=F>3:2 &?:G6CD:EJ]k^AmkAmu:?2?4:2= |@56=D s6D:8?65 pC@F?5 w@H {:76 $4:6?46D s6G6=@Ak^AmkAm{:76 D4:6?46 4@>A2?:6D 5:776C 7F?52>6?E2==J 7C@> >2?J @E96C 6>6C8:?8 3FD:?6DD6D] r2A:E2= C6BF:C6>6?ED 2C6 7C6BF6?E=J 5C:G6? 3J D4:6?E:7:4[ 4=:?:42= 2?5 C68F=2E@CJ >:=6DE@?6D C2E96C E92? 4@?G6?E:@?2= C6G6?F6 8C@HE9] s6G6=@A>6?E E:>6=:?6D 42? DA2? J62CD[ 2?5 D:8?:7:42?E 6?E6CAC:D6 G2=F6 >2J 36 4C62E65 H6== 367@C6 2 AC@5F4E C62496D E96 >2C@56=D E92E >@C6 4=@D6=J C67=64E 9@H =:76 D4:6?46 :??@G2E:@? 24EF2==J AC@8C6DD6D]k^AmkAm“u@C >6[ E9:D F=E:>2E6=J 4@>6D 324< E@ D4:6?46 2?5 E96 A6@A=6 :E :D :?E6?565 E@ D6CG6[” (6DE D2:5] “!2E:6?ED 2?5 A2E:6?E 4@>>F?:E:6D @7E6? F?56CDE2?5 3@E9 E96 FC86?4J @7 F?>6E ?665 2?5 E96 C62=:E:6D @7 =:G:?8 H:E9 5:D62D6 :? H2JD E92E 42? 255 :>A@CE2?E A6CDA64E:G6 E@ E96 56G6=@A>6?E AC@46DD 2?5 E96J D9@F=5 36 23=6 E@ :?G6DE :? E96D6 4@>A2?:6D] pD H6 E9:?< 23@FE ?6H H2JD E@ DFAA@CE 6>6C8:?8 =:76 D4:6?46 4@>A2?:6D[ H6 H2?E E9@D6 A6CDA64E:G6D C6AC6D6?E65 2=@?8D:56 E9@D6 @7 D4:6?E:DED[ 6?EC6AC6?6FCD[ 2?5 :?G6DE@CD]”k^AmkAmq$x 6IA64ED E96 25G:D@CJ 3@2C5 E@ AC@G:56 DEC2E68:4 8F:52?46 2D E96 4@>A2?J 56G6=@AD q:@%649 uF?5:?8 !@CE2= 2?5 6G2=F2E6D 255:E:@?2= 2AAC@2496D E@ 6IA2?5:?8 2446DD E@ 42A:E2= 7@C =:76 D4:6?46 4@>A2?:6D]k^AmkAm“~FC 7@4FD :D DEC2:89E7@CH2C5[” r9C:DE:6 D2:5] “%96C6 :D C6>2C6C8:?8 4@>A2?:6D[ 2?5 E@@ >F49 @7 :E 6?4@F?E6CD 2 7:?2?4:?8 82A 367@C6 :ED A@E6?E:2= 42? 36 G2=:52E65] (6 H2?E E@ 3F:=5 7:?2?4:2= :?7C2DECF4EFC6 E92E 8:G6D >@C6 @7 E92E D4:6?46 2? @AA@CEF?:EJ E@ >2A2?J 56G6=@AD A=2E7@C>D[ E@@=D[ 2?5 7:?2?4:2= DECF4EFC6D :?E6?565 E@ 6IA2?5 2446DD E@ 42A:E2= 7@C 3:@E649?@=@8J[ A92C>246FE:42=[ >65:42= E649?@=@8J[ 5:28?@DE:4[ 5:8:E2= 962=E9[ 2?5 @E96C =:76 D4:6?46 4@>A2?:6D] q:@%649 $@4:2= x?4] :D E96 A2C6?E 4@>A2?J @7 q:@%649 uF?5:?8 !@CE2= {{r]k^AmkAmu@C >@C6 :?7@C>2E:@?[ G:D:Ei k2 9C67lQ9EEADi^^HHH]3:@E649]D@4:2=Qm9EEADi^^HHH]3:@E649]D@4:2=k^2mk^AmkAmp3@FE q:@%649 uF?5:?8 !@CE2=k^AmkAmq:@%649 uF?5:?8 !@CE2= :D 2? $tr\C68:DE6C65 7F?5:?8 A@CE2= 2?5 ux}#p >6>36C 7@4FD65 6I4=FD:G6=J @? =:76 D4:6?46 4@>A2?:6D C2:D:?8 42A:E2= F?56C #68F=2E:@? rC@H57F?5:?8] %96 A@CE2= 6?23=6D 6=:8:3=6 4@>A2?:6D E@ C2:D6 FA E@ Sd >:==:@? :? 42A:E2= 2??F2==J 7C@> :?5:G:5F2= :?G6DE@CD H9:=6 AC@G:5:?8 :?G6DE@CD 2446DD E@ AC:G2E6 =:76 D4:6?46 :?G6DE>6?E @AA@CEF?:E:6D F?56C #68F=2E:@? rC@H57F?5:?8]k^AmkAmx?G6DE>6?E @AA@CEF?:E:6D @776C65 E9C@F89 q:@%649 uF?5:?8 !@CE2= 2C6 DA64F=2E:G6[ :==:BF:5[ 2?5 :?G@=G6 2 9:89 568C66 @7 C:D6?E] %9:D AC6DD C6=62D6 :D 7@C :?7@C>2E:@?2= AFCA@D6D @?=J 2?5 5@6D ?@E 4@?DE:EFE6 2? @776C E@ D6== @C D@=:4:E2E:@? @7 2? @776C E@ 3FJ 2?J D64FC:EJ] p?J D64FC:E:6D @776C:?8 4@?5F4E65 E9C@F89 q:@%649 uF?5:?8 !@CE2= :D >256 @?=J AFCDF2?E E@ 2AA=:423=6 @776C:?8 >2E6C:2=D 7:=65 H:E9 E96 &]$] $64FC:E:6D 2?5 tI492?86 r@>>:DD:@?]k^AmkAmu@C >@C6 :?7@C>2E:@?[ G:D:Ei k2 9C67lQ9EEADi^^HHH]3:@E649]7F?5Qm9EEADi^^HHH]3:@E649]7F?5k^2mU?3DAjk^AmkAm|65:2 r@?E24Eik^AmkAm{66\p?? |FCA9Jk^AmkAmq:@%649 $@4:2= x?4k^AmkAmk2 9C67lQ>2:=E@i=662??o3:@E649]D@4:2=Qm=662??o3:@E649]D@4:2=k^2mU?3DAjk^AmkAm k^Am
Anixa Biosciences Appoints UPenn's Dr. Carmen Guerra to Cancer Business Advisory Board
/PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer,...
Anixa Biosciences Appoints UPenn's Dr. Carmen Guerra to Cancer Business Advisory Board
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced the appointment of Carmen Guerra, M.D., M.S.C.E., F.A.C.P., to its Cancer Business Advisory Board.
How AI is rewriting the rules for medicine and biotech in Mass.
Three Mass. health care leaders explain why AI in medicine is about more than speed—it's changing how scientists and doctors approach patient care.
Dealroom.co | RegCell raises $44M Series A to move Nobel-winning Treg science to the clinic
What's the deal? RegCell, an Emeryville, California biotech co-f…
Your face gets antiaging science. Now what?
Core Biogenesis and Faravelli are testing whether the biotech behind facial skincare can be scaled up to treat the rest of the body.
Axios Live: Research and manufacturing investments boost Philadelphia's biotech role
Significant investments in biotech research and manufacturing are positioning the Philadelphia region for new jobs and broader economic growth
Wilmington health tech founder launches new venture
Several years after launching his health tech startup Artemis Immersive, founder Adam Isley is setting his sights on new horizons. Co-founded in 2023 by husband-and-wife Adam Isley and Kaylan Barbrey, along with Matthew Raffa and Bill Blakesley, Artemis Immersive began as a spatial medtech company that created digital renderings of medical scans for viewing in augmented reality (AR). Isley said the firm, which won an NC Tech award in the Biotech + HealthTech Innovation category last year, has raised $1.2 million in total in seed funding since launching. Isley has since created a new venture, Research and Me, building on the Artemis platform. Like Artemis Immersive’s core software, VoxScan, Research and Me combines health data with artificial intelligence in a 3D interactive environment to help patients better understand health outcomes and provide integrative wellness support. While the Artemis product is no longer Isley’s primary focus, he said the company’s technology and ambitions have evolved into different ventures, like Research and Me. "It's a different venture building on the Artemis platform, and there'll probably be more,” Isley said. He added, "I was very disappointed in the quality of the information available to general patients about their healthcare... I wanted to give patients more and a better plate of choices." Research and Me is still in its beta phase, Isley said, with usability testing ongoing in partnership with the firm’s partner, Medicap Pharmacy and Wellness Center, owned by Barbrey. "As someone who's kind of dedicated their life to working in healthcare, I've tried to bring this spirit and passion to it,” he said, “and a lot of the resources that we'll be providing are free — like a base level of free care for any patients, or medical education if they've got specific conditions." Isley describes Research and Me as a “patient-first” platform designed to securely store and pseudonymize health data and use AI and medical literature to generate insights. The insights are presented in an interactive 3D environment for patients and providers to explore conditions, treatments and wellness plans together. "It's almost like a democratization of understanding medical information," Isley said. "We take a whole bunch of clinical data, we take a whole bunch of peer‑reviewed, published studies on PubMed, and we try to turn them into chunks of information that normal humans can understand." Like VoxScan, the Research and Me platform lets users interact with 3D anatomical models for visualization. The platform provides a space for tracking, notes and insights. The platform also supports video conferencing, Isley said, allowing providers or coaches to examine models and data together. "We wanted to create a safe environment where you can start to learn and experiment with new features about your health, using agents to do that,” Isley said. While Research and Me is in beta-phase testing with Medicap Pharmacy, Isley said he envisions the platform serving a wellness-oriented community, working with sports performance clinics and hormone optimization. Isley, who is working towards a wellness-coach board certification, also plans to offer functional wellness consults through the platform. Long‑term, Isley says he wants the platform to embody an “integrative health practitioner” approach, “connecting experts of different fields and specializations in a way that they can make a greater impact in people's lives.” “For people in the state of North Carolina, it's already a win,” Isley said of the Medicap rollout, noting that partner clinics get “immediate resources for learning about their health and wellness conditions… out of the box.” Isley plans to launch Research and Me’s provider portal in 2028 and begin pursuing integrations with larger systems, he said.
As elective surgical volumes drag in 2026, health system execs say solid demand is still in sight
Though surgical volumes were a sore spot for major for-profit health systems in the opening half of 2026, executives said this week they are optimistic those service lines will stay afloat for the | In fireside chats this week, leaders of the country's largest for-profit systems acknowledged a slowdown in demand that will generally continue through 2026. They also affirmed continued investments to meet future anticipated demand, particularly in ambulatory settings.
AI and Biotechnology Risks Demand Science Diplomacy
Track-two science diplomacy can provide vital safeguards on AI.
The Escalator: Inizio, Health Catalyst, Eversana and more
See which leaders are on the move across the pharma, biotech and medical marketing industries.
A booming business on Wall Street would love more biotechs to quietly die
Once disparaged, reverse mergers have become so popular that some deal experts question whether there are enough quality shell companies to meet the demand.
Luma locks down 15-year, $410M fund for life science investments
Luma Group today announced the final close of its inaugural life sciences venture capital fund, totaling $410 million. The New York-based investment firm has had a grip on life sciences since its founding in 2023. The funds unveiled today, dubbed LumaBio Fund I, include investments that have already been made into more than 10 biotechs. They include the likes of eye disease-focused Character Biosciences, rebranded Belgian biotech Coultreon Biopharma and cellular rejuvenation company Altos Labs. The fund saw early success when one of the companies it co-founded, called Vaccine Company, was picked up by Eli Lilly earlier this year for up to $1.55 billion. The acquisition of the in vivo nanoparticle technology-focused biotech formed part of a trio of vaccine buys for the Big Pharma, which has itself been on a prolonged spending spree in 2026. Luma's fund is structured as a 15-year investment with plans to support groundbreaking science and support companies through key milestones from discovery to commercialization, Luma explained in the release. "We founded Luma Group on the belief that extraordinary science, supported by patient, long-term capital, has the power to improve millions of lives," Joshua Fink, founder and managing member of Luma Group, said in the release. "This fund represents more than capital—it is a commitment to partnering with extraordinary innovators as they translate visionary science into life-changing medicines."
SC's Emerging Biotech Industry Receives National Recognition
Genetic Engineering & Biotechnology News (GEN) recently named the Palmetto State among its “Regional and State Clusters to Watch” in its first-ever Next 10 U.S. Biopharma Clusters report, highlighting emerging life sciences ecosystems beyond...
Osaka has the science. Now it needs the business
Osaka is striving to turn world-class life sciences research into a global healthcare industry - testing whether Japan's pharma and biotech sector can finally scale internationally.
Osaka has the science. Now it needs the business
Osaka is striving to turn world-class life sciences research into a global healthcare industry - testing whether Japan's pharma and biotech sector can finally scale internationally.
Osaka has the science. Now it needs the business
Osaka is striving to turn world-class life sciences research into a global healthcare industry - testing whether Japan's pharma and biotech sector can finally scale internationally.
Osaka has the science. Now it needs the business
Osaka is striving to turn world-class life sciences research into a global healthcare industry - testing whether Japan's pharma and biotech sector can finally scale internationally.
Merrimack Anheuser-Busch Property purchased by United Therapeutics Corporation
Biotechnology firm United Therapeutics Corporation has acquired the former Anheuser-Busch brewery site in Merrimack for $47 million, according to sources familiar with the matter. The transaction secures one of Southern New Hampshire’s largest industrial parcels, spanning nearly 300 acres off Daniel Webster Highway
Billionaire family offices back health care and biotech startups in August
The personal investment firms of titans like Stanley Druckenmiller are backing innovations in gene editing, drug discovery and more.
NSF launches three new Science and Technology Centers with $90M investment in transformative research
The U.S. National Science Foundation is investing $90 million over five years to support three new NSF Science and Technology Centers (NSF STC). These centers will advance American leadership in science and technology, strengthen the nation’s STEM workforce, and accelerate innovation in fields ranging from artificial intelligence and biotechnology to fusion energy and robotics., , , , The three centers will bring together researchers from universities, national laboratories, industry, and oth...
Rice-developed BuoyBeads bring biotechnology lessons to high school classrooms
A biotechnology kit developed at Rice allows high school students to create living materials.
Empowering Young Scientists: Caldwell University’s Biotechnology Research Fellowship Program Completes Its Second Year
Caldwell, NJ – Caldwell University’s Biotechnology Research Fellowship Program completed its second year on Friday, August 14, 2026. This dynamic, three-week intensive placed high school fellows directly into the world […]
Boston Scientific hit by cyberattack causing ‘disruptions’ to parts of its business
This year has seen a growing number of medtechs hit by cyberattacks, and now Boston Scientific has become the latest victim. In an SEC filing posted Aug. 26, the medtech giant said it had detected a “cybersecurity incident” the day before. The incident has affected certain parts of its information technology systems, something that “has resulted in a global disruption to the company’s operations.” The incident has hit not just its information systems but also its business applications, which “support aspects of the Company’s operations,” it said in the filing. This includes its ability to process and ship customer orders. Boston Scientific said it is working to restore the systems, but the timeline remains unknown. Related Baylor Genetics hit by cybersecurity attack targeting patient, staff information As the company investigates the incident, it remains unclear how significantly its business will be affected. “Accordingly, the Company has not yet determined whether the incident is reasonably likely to have a material impact.” The company’s shares were down 3.5% in premarket trading as the news broke. This adds another layer of pressure for the medtech, which last month revealed a new global restructuring program that starts this year and is slated to be completed by 2029. The company said at the time that it “does expect some headcount reductions to result from these restructuring activities,” but did not provide any numbers or specify areas where the cuts may be made. It added, however, that new jobs are also set to be “created in areas of growth.” It was also forced to cut its sales guidance in Q2, saying in late July that it now expects full-year 2026 organic revenue growth of 5% to 6%, down from its previous guidance of 6.5% to 8%. Boston Scientific is one of a growing number of life sciences companies, notably medtechs, that have been hit by cyberattacks this year. These include Abbott, iRhythm, Medtronic and Stryker, as well as Big Pharmas Amgen and Novo Nordisk.
N.C. A&T’s Honors College Hosts 2026 Honda STEM Summer Camp on Biotechnology, Data Science
N.C. A&T’s inaugural Honda STEM Summer Camp gave 29 students hands-on experience in biotechnology, data science, AI and emerging technologies through research, mentorship and industry engagement.
Adaptive Biotech co-founder raises $15M for new startup to rethink how AI trains on science
Harlan Robins (Photo via Harell Data) Harlan Robins spent years as the co-founder and chief scientific officer of Adaptive Biotechnologies, helping build
After program reductions, Calvin University debuts engineering, computer science school
The school is expected to enhance core offerings in fields like biotechnology and artificial intelligence.
Pace appoints Andy Fenny as president to drive life science growth
Pace, a science and technology company, has appointed Andrew (Andy) Fenny as president of Pace Life Sciences, the organization’s life sciences division, to lead the business into its next phase of strategic growth with a focus on expanding support and capacity for pharmaceutical and biotech clients across the development cycle.
Screwworm neutralizer: insect sterilization | Investors Lab
The fight against screwworm has moved beyond traditional government programs into an arena ripe for biotech intervention:
Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
/PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the...
AbCellera women’s health data top ‘most aggressive upside scenario,’ putting Astellas and Bayer on notice
AbCellera has reported phase 2 results “beyond even the most aggressive upside scenario” that its CEO dared to consider, boosting the biotech’s chances of challenging Astellas and Bayer for a women’s health market. The phase 2 clinical trial compared ABCL635, an antibody targeting NK3R, to placebo in patients with hot flashes caused by menopause. Investigators enrolled 92 postmenopausal women experiencing a mean of about 10 moderate or severe hot flashes per day. By Week 4, the number of moderate or severe hot flashes had fallen by a mean of 8.8 on ABCL635 and by 3.5 on placebo. That statistically significant, placebo-adjusted reduction of 5.3 hit the trial’s primary endpoint. The level of efficacy also cleared the bar set by existing drugs. While cross-trial comparisons can be misleading, AbCellera CEO Carl Hansen, Ph.D., had seen enough to start hyping the program. “We now view ABCL635 as a potential best-in-class non-hormonal therapy with strong differentiation against approved NK3R competitors across all important dimensions, including efficacy, safety, dosing and convenience,” Hansen said on a Monday morning conference call with investors to discuss the data. “We believe ABCL635 is now a highly de-risked program.” Last week, Hansen used AbCellera’s earnings call to set expectations for readout, with the CEO defining success as a clean safety profile and efficacy comparable to the two approved small molecules. The data vaulted over that bar. Astellas linked (PDF) one of the small molecules, Veozah, to placebo-adjusted reductions in hot flash frequency of 2.1 and 2.6 at Week 4 of its two phase 3 trials. Bayer reported (PDF) placebo-adjusted reductions of 3.04 and 3.29 at Week 4 of pivotal studies for its small molecule, Lynkuet. At 5.3, the placebo-adjusted reduction in AbCellera’s trial comfortably cleared the standard set by the incumbents. Veozah and Lynkuet came to market based on evidence of their ability to reduce the frequency and severity of hot flashes. AbCellera’s phase 2 study covered both endpoints, with the Canadian biotech reporting a mean reduction in severity of 1.4 points at Week 4 on ABCL635, compared to 0.3 points for placebo. Again, the placebo-adjusted result compares favorably to data on Veozah and Lynkuet. Analysts shared Hansen’s enthusiasm for the data. The phase 2 results “firmly validate ABCL635 as a potentially best-in-class treatment,” BMO Capital Markets analysts said in a note to investors Monday. ABCL635’s apparent efficacy edge “is likely attributable to the higher dosing/target engagement the asset is able to reach vs. the oral agents due to its wider therapeutic index,” the analysts added. The analysts, who model $2.3 billion in unadjusted peak sales for ABCL635, flagged the safety profile as another positive of the phase 2 readout. While Veozah carries a boxed warning for liver damage, nobody on ABCL635 in the phase 2 trial had elevated liver enzymes or bilirubin values. If replicated in phase 3, the lack of a liver signal could allow approval without the monitoring requirements imposed on Veozah. Investors appeared equally enthused, sending AbCellera's stock up 32% to $9.21 in premarket trading Monday from a Friday closing price of $6.93. Next, AbCellera will collect the Week 12 data and talk to its advisors about further development. The results open up “a wide variety of possibilities of how we might take this forward into phase 3 studies to truly maximize the value of the asset and make sure that ABCL635 is able to demonstrate its differentiation potential,” Sarah Noonberg, M.D., Ph.D., AbCellera’s chief medical officer, told investors.
Supporters of a bipartisan bill say America’s biotechnology future depends on measurement science
I think the success will be that there are uniform standards that could be used by AI, by international scientists," said Congresswoman April McClain Delaney.
Viewpoint: Europe needs a new scientific contract
The White House's new science strategy should be required reading in the Berlaymont and every European capital.Not because Europe should copy it. Parts of it should concern Europeans deeply. But because it asks the question Europe has so far avoided while steadily losing ground in the global race for technological leadership.Europe already possesses many of the world's finest universities, scientists and research-intensive companies. It produces world-leading research in fields ranging from quantum technologies and biotechnology to climate science. Yet time and again Europe generates the scientific breakthroughs while others build the companies, industries and strategic advantages around them, particularly in digital technologies. Increasingly, we find ourselves regulating technologies whose underlying capabilities were developed elsewhere.This is not primarily a scientific failure. It is an institutional one.The settlement that shaped modern science policy emerged after the Second World War. In Science, the Endless Frontier, Vannevar Bush argued that governments should invest in fundamental research while protecting scientists from political direction. Public investment was justified precisely because no government, university or company could predict where the next transformative discovery would emerge.That scientific contract served liberal democracies extraordinarily well. It underpinned decades of advances in medicine, computing, energy and communications, but the world for which it was designed no longer exists.Artificial intelligence is transforming not only technology but the production of knowledge itself. Advanced chips, computing power, data and scientific instruments have become strategic assets. Scientific knowledge now diffuses globally almost instantly. Competitive advantage increasingly lies not in making discoveries first, but in possessing the infrastructure, capital, engineering capability and institutions required to translate those ideas into products, industries and strategic advantage.The old boundaries between science, industrial policy, national security and geopolitics have largely disappeared. Dual-use technologies now underpin both economic power and military deterrence.The US has recognised this shift. In July, the White House published Science: A New Golden Age, a comprehensive attempt to rethink the relationship between science and national power. The report builds on Bush's legacy, but departs from his framework in important ways. Science is no longer treated simply as the source of future discoveries. It is presented as the foundation of economic resilience, technological leadership and national security. AI, advanced infrastructure and the capacity to build become as important as discovery itself.Yet the report also reveals a striking paradox. The same administration calling for “a new golden age” of US science has simultaneously proposed deep cuts to the federal research enterprise while expanding political influence over the allocation of public research funding. Europe should therefore distinguish between the report's diagnosis and its prescription. The diagnosis, that science has become a strategic asset, is compelling. But the prescription is self-defeating. Long-term technological leadership depends on strong universities, academic freedom and the institutional autonomy that makes scientific discovery possible. This distinction matters. Bush's achievement was never simply to make science serve national strength. It was to establish a division of labour in which governments invested in research without attempting to direct discovery itself. Scientific breakthroughs emerge precisely because researchers retain the freedom to pursue questions whose value cannot yet be demonstrated and whose conclusions cannot be anticipated.Neither China, nor the USAs science becomes more strategically important, the temptation to politicise it inevitably grows. But scientific freedom is not an obstacle to technological leadership, it is an essential precondition.China represents the opposite model. For decades it has integrated science, manufacturing, infrastructure and industrial policy into a single national strategy. Its ability to mobilise resources around critical technologies is formidable. But it does so within an authoritarian system where scientific priorities are increasingly inseparable from political power.Europe should imitate neither model. It should learn from the strategic ambition of the US without importing its growing politicisation of science. And it should learn from China's capacity to build without adopting its concentration of power.Instead, Europe needs a scientific contract of its own. Bush's scientific contract protected the freedom to discover because the defining challenge of the 20th century was producing new knowledge. Europe's next scientific contract must preserve that freedom while ensuring that scientific discoveries can be converted into technological, industrial and strategic capability. Because in a transactional world, Europe's freedom to shape its own future depends on its capacity to build it.Related articlesThe US ‘golden age’ science strategy: what Europeans need to knowEuropean researchers sound the alarm that Trump rule changes will hit cooperationNIH turmoil risks reciprocal EU-US access to health research fundingThis does not mean subordinating free science to competitiveness or industrial policy. On the contrary. Scientific autonomy remains the first principle of Europe's next scientific contract. Governments should not direct scientific discovery. Their responsibility is to ensure that Europe's scientific, industrial, financial and regulatory institutions work together rather than in isolation.Meeting that responsibility requires far more than research funding. European researchers need access to world-class computing infrastructure, advanced laboratories, shared datasets and scientific facilities. Innovative companies need patient capital, testing environments and a genuine single market in which they can scale without facing 27 different regulatory regimes. Public procurement must evolve from purchasing existing technologies to creating markets for new ones. Regulators must become partners in experimentation rather than guardians of yesterday's rules.A connecting architectureEurope does not need to invent the Defense Advanced Research Projects Agency (Darpa) model from scratch. Britain's Aria, Germany's Sprind and Wellcome Leap already show that Europe can build institutions capable of taking high-risk, mission-oriented bets while preserving democratic accountability. The challenge now is not to create more isolated initiatives, but to connect them to Europe's broader scientific, industrial and financial system so that breakthrough discoveries can scale.Above all, Europe must stop treating research, innovation, industrial policy, finance and security as separate policy domains. The challenge is no longer to create excellent institutions in each of these fields, but to make them work as one European innovation system. Europe's strength will increasingly depend not on excellence within institutions, but on excellence across them.Europe's ambition should be neither to imitate the US nor to emulate China. It should demonstrate that scientific freedom, democratic legitimacy and technological capability are not competing objectives, but mutually reinforcing strengths. In an age of geopolitical rivalry, Europe's greatest advantage may ultimately be its ability to attract the world's best talent by combining scientific freedom, democratic openness and technological ambition.Bush's scientific contract helped define the 20th century because it protected the freedom to discover. Europe's challenge is not to abandon that achievement but to extend it. The defining task of Europe's next scientific contract is to preserve the freedom to discover while building Europe's capacity to translate scientific discovery into technological power.Kaare Nielsen is founder of Pomus, a Danish think tank on science and innovation.
Sanofi suspends chronic lung disease phase 2 study, tied to ‘strategic business reasons’
Sanofi halted a phase 2 trial testing a monoclonal antibody, SAR445399, in non-cystic fibrosis bronchiectasis, Fierce Biotech has learned. The trial, which began only back in April, was a randomized, double-blind, placebo-controlled study to measure the reduction in mucus plug score following treatment with SAR445399 compared with placebo in adults aged 18 to 80 years with NCFB, a chronic lung disease. The trial was officially reported as halted on July 29, the day before Sanofi’s second-quarter earnings call. The decision to pause the trial was made “as part of a company-wide portfolio review for strategic business reasons,” and not due to safety concerns, a Sanofi spokesperson told Fierce. The move to pause the NCFB trial comes during a trying time for Sanofi following a year filled with a series of trial fails. In February, the French pharma ousted CEO Paul Hudson and appointed Merck KGaA leader Belén Garijo, M.D., Ph.D., to steer the ship. Since then, Garijo has been doing a deep dive on correcting the company’s strewn R&D and clinical strategies. On July 24, Sanofi scrapped amlitelimab for atopic dermatitis, despite its lore as being a potential $5 billion blockbuster. During its second-quarter report, the company abandoned two more assets, balinatunfib and itepekimab, following failed trial results in psoriasis and chronic obstructive pulmonary disease, respectively. SAR445399, only first revealed by Sanofi in 2023, is an anti-interleukin-1 receptor 3 monoclonal antibody developed to block the interleukin 1, 33, and 36 cytokine pathways. These pathways can be important in chronic immune-related dermatologic diseases, such as atopic dermatitis and hidradenitis suppurativa, as well as respiratory conditions, such as NCFB. Related Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues NCFB affects roughly half a million people in the U.S., with a global incidence of greater than one million cases. In August 2025, Insmed received FDA approval for Brinsupri, a DPP1 inhibitor targeting neutrophil activation, for treatment of NCFB in adults and kids ages 12 and older. The British biotech Infex Therapeutics showed promising NCFB phase 2a data using their monoclonal antibody, INFEX702, which acts by disabling Pseudomonas aeruginosa, a bacteria known to be a major pathogen of NCFB. Sanofi is currently running a separate phase 2 study testing SAR445399 as a potential treatment for the inflammatory skin condition hidradenitis suppurativa.
Scientists use gene editing to create hypoallergenic dogs
Scientists at a biotech company have used gene editing to create two hypoallergenic beagles that don't trigger allergies.
Senate Panel To Examine Biotech's Role in U.S. Health Resilience
Senate Finance Committee investigates biotech's impact on U.S. health resilience as China gains pharmaceutical advantage. Hear expert testimony August 4.
FDA weighs a new kind of flu shot based on technology RFK Jr. has questioned
The FDA is poised to render a decision on Moderna's mRNA-based flu shot, which could be the first of its kind to market. The decision is expected to reverberate throughout the biotech industry.
Biotech is Back: A Wave of Life Science Deals is Pumping Cash into the Sector
Learn more about the latest updates in legal, with expert commentary and insights from trusted attorneys from Foley Hoag LLP. Foley Hoag is a professional community of highly qualified attorneys from all over the US.
AI Cognitive Health Startup Mantis Biotech Rethinks How Women Are Diagnosed
The AI Catching Brain Fog, ADHD, And Dementia Between Doctor Visits
Killing slime: an AI-first biotech solution | Investors Lab
We love public science lessons, like the algae debacle that turned Washington, D.C.'s Lincoln Memorial Reflecting Pool a vibrant green this summer after a renovation. It's not exactly a new development. Algal blooms have intermittently plagued the site for generations, including during the last big overhaul in 2012. But the latest episode lingers despite treatments with hydrogen peroxide and an ozone nanobubble system. As Bethany Brookshire makes clear for Science News, there's another option that might have managed the crisis far more effectively, had it been used from the start.
The VA could help America win the biotechnology race with China
“Together, HHS, the VA, and the DOD form a strong American innovation ecosystem — one that China and other competitors cannot easily replicate,” writes former VA Secretary David Shulkin.
Why 3 secretive biotechs are keeping their science close to the chest
Startups like Altos Labs are keeping pipeline details scarce to protect their ideas from competitors — but some experts say stealth only works for biotechs with deep pockets.
FDA rejects application for new oral MR imaging contrast agent
Biotechnology firm Ascelia Pharma is working to roll out Orviglance, a novel manganese-based product for visualizing focal liver lesions during MRI, but faced a recent setback.
Biotech is ‘leading innovative science, not universities’
Sharper mission and team ethos of pharma companies make them more effective than university labs, says Nobelist Fred Ramsdell
Girl, 6, Died After Experimental Gene-Editing Treatment in China: Science
A young girl died after receiving an experimental gene-editing treatment in a clinical trial in Shanghai, Science reported, raising questions about regulatory oversight and transparency as China rapidly expands its biotechnology ambitions.
Biotech experts want FDA drug reviews based on science, not politics
Biotech experts call for the FDA to prioritize scientific expertise over political influence in drug reviews amid recent leadership changes and staffing challenges.
NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying...
Biotech experts want FDA drug reviews based on science, not politics
Biotech experts and industry executives are calling plans by the U.S. Food and Drug Administration — hit by job cuts last year — to hire thousands of employees and update clinical-trial standards encouraging, but want assurance that politics will not interfere in the agency's drug-review process.
Biotech experts want FDA drug reviews based on science, not politics
Biotech experts and industry executives are calling plans by the U.S. Food and Drug Administration — hit by job cuts last year — to hire thousands of employees and update clinical-trial standards encouraging, but want assurance that politics will not interfere in the agency's drug-review process.
Biotech experts want FDA drug reviews based on science, not politics
July 22 (Reuters) - Biotech experts and industry executives are calling plans by the U. Food and Drug Administration — hit by job cuts last year — to hire thousands of employees and update clinical-trial standards encouraging, but want assurance that politics will not interfere in the agency's drug-review process.
Gov. Shapiro highlights life sciences growth with visit to Philadelphia biotech incubator
The $125 million Innovate in PA 2.0 initiative aims to help startups grow, commercialize new technologies and keep life sciences companies in Pennsylvania.
Rebuilding the Innovation Engine: How We Got Here And What Comes Next
Federal investment in basic science built America’s innovation engine, but declining support is threatening U.S. leadership, writes Dietrich Stephan, Ph.D.
Harvard Scientists Turned a Silicon Chip Into a DNA Factory
Harvard scientists have built a silicon chip that writes DNA using electricity and water, pointing toward a cleaner future for DNA manufacturing and biotechnology.
Merck’s cholesterol pill gets US FDA approval
Merck said on Thursday the U.S. FDA has approved its cholesterol pill, the first of its kind to receive the health regulator’s nod, bolstering the drugmaker’s efforts to diversify beyond its blockbuster cancer treatment Keytruda.
The opioid offensive: Fighting fentanyl | Investors Lab
As the clinical-stage biotech sector tackles this multibillion dollar public health imperative, a mix of established players and venture-backed innovators are making strides:
AB Science ends three studies in multiple sclerosis, other immune conditions
The trials, which were testing the tyrosine kinase inhibitor masitinib, had previously been paused. AB Science’s decision not to resume them was a matter of prioritization, not safety, the biotech said.